Gastroenterology

Clostridium difficile could be mutating to transfer from pets to humans.

Patients using statins had a 4.3% infection rate compared with a 7.8% rate for those not taking statins, concluding that statins may be associated with a 20% risk reduction.

Patients receiving long-term care more likely to test positive for VRE than toxigenic C. difficile.

Patients who consumed vinegar daily along with a restricted calorie diet lost more weight and saw improved BMI scores compared to those just on the diet.

Long-term care facility residents with advanced dementia have substantial dysbiosis of their gut microbiome which may be able to identify subjects at high risk of C. difficile colonization.

Hospital-specific models allow for earlier and more accurate identification of high-risk patients to better target infection prevention strategies.

The update includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis.

Developers hope the beta-3 agonist can report consistent efficacy and tolerability.

Older or immunocomprimized patients incur a large healthcare resource burden with C. difficile.

The bidirectional spread of the strain between farm animals and humans may represent an unappreciated route disseminating antimicrobial resistance genes between humans and animals.

The mortality rate in C. difficile-infected patients with acute kidney infection is decreasing, from 23.9% to 14.8%, but hospitalizations increased significantly by 1.8 over the study period.

When it comes to C. difficile prevention, less may be more.

If approved, prucalopride will be the only readily available 5-HT4 agonist in the US for CIC in adults.

Preliminary study results showed that Fecal donor-unrelated donor mix for initial Clostridium difficile infection is associated with specific bacterial communities that do not resemble the donors’ sample.

The NeoTract product was originally indicated to treat those with BPH aged 50 years and older.

The first patients have been enrolled into the first-in-human IMM-529 clinical study for the treatment of Clostridium difficile infection.

The study highlights potential racial and medical characteristics that affect the access of the patients to FMT.

The novel solution is being investigated for patient acceptability and compliance to bowel cleansing.

Reducing delays can help stop the spread of the infection and initiate treatment to patients quickly.

Complementary and alternative medicine can decrease the rate of antimicrobial resistance and reduce treatment costs.

Implementing a standardized C. difficile screening protocol was associated with a significant decrease in the rate of HO-CDI among BMT patients

The approval has expanded ferumoxytol's indication to include all adults with iron deficiency anemia.

While maintaining contact precautions for extended periods can keep from spreading, unnecessarily long isolation can negatively impact care.

Trulance is the only treatment thought to replicate the pH-sensitive activity of uroguanylin.